scholarly journals Management of the urethra in urothelial bladder cancer

2013 ◽  
Vol 3 (6-S4) ◽  
pp. 211 ◽  
Author(s):  
Androniki Kanaroglou ◽  
Bobby Shayegan
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Poor Prognosis ◽  
Urothelial Cancer ◽  
Standard Of Care ◽  
Urothelial Bladder Cancer ◽  
Risk Of Recurrence ◽  
Urothelial Bladder ◽  
Bladder Substitution ◽  
Contemporary Management

The standard of care in the management of invasive urothelialcancer of the bladder is radical cystectomy and pelvic lymphadenectomy.Although uncommon, recurrence of disease in the retainedurethra following cystectomy carries a poor prognosis. The needfor assessment of risk of recurrence is greater now than ever withwider adoption of orthotopic bladder substitution. This reviewwill address the contemporary management of the urethra followingcystectomy for urothelial cancer.

POD-09.10: Prognotic factors in patients with urothelial bladder cancer submitted to radical cystectomy

Urology ◽  
2007 ◽  
Vol 70 (3) ◽  
pp. 31
Author(s):  
F.P. da Fonseca ◽  
A.L. de Godoy ◽  
G.C. Guimaraes ◽  
I.N. Nishimoto ◽  
S.C. Zequi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder

Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer

2020 ◽  
Vol 38 (3) ◽  
pp. 76.e1-76.e9 ◽  
Author(s):  
Giuseppe Rosiello ◽  
Carlotta Palumbo ◽  
Sophie Knipper ◽  
Angela Pecoraro ◽  
Cristina Dzyuba-Negrean ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Oncologic Outcomes ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder

Treatment of metastatic bladder cancer

2017 ◽  
Author(s):  
Fabio Calabrò ◽  
Cora N. Sternberg
Keyword(s):  
Bladder Cancer ◽  
Urothelial Cancer ◽  
Clinical Investigation ◽  
Good Prognosis ◽  
New Drugs ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
Molecular Patterns ◽  
The Impact

Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led to clinical investigation of several therapeutic targets. To date, these agents have yet to demonstrate an improvement in overall survival. Urothelial cancer is extremely sensitive to checkpoint inhibition with both anti PD-1 and anti PDL1 antibodies. The future seems brighter with the advent of these new therapies.

Sign in / Sign up

Export Citation Format

Share Document